MX2013002111A - Metodos y composiciones para el tratamiento de metastasis del cancer. - Google Patents

Metodos y composiciones para el tratamiento de metastasis del cancer.

Info

Publication number
MX2013002111A
MX2013002111A MX2013002111A MX2013002111A MX2013002111A MX 2013002111 A MX2013002111 A MX 2013002111A MX 2013002111 A MX2013002111 A MX 2013002111A MX 2013002111 A MX2013002111 A MX 2013002111A MX 2013002111 A MX2013002111 A MX 2013002111A
Authority
MX
Mexico
Prior art keywords
compositions
treating cancer
cancer metastasis
methods
metastasis
Prior art date
Application number
MX2013002111A
Other languages
English (en)
Inventor
Sheng-Yung Liu
Wu-Che Wen
Original Assignee
Golden Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corp filed Critical Golden Biotechnology Corp
Publication of MX2013002111A publication Critical patent/MX2013002111A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos y composiciones para el tratamiento de metástasis por cáncer por compuestos de ciclohexenona.
MX2013002111A 2012-02-23 2013-02-22 Metodos y composiciones para el tratamiento de metastasis del cancer. MX2013002111A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261602489P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
MX2013002111A true MX2013002111A (es) 2013-08-28

Family

ID=48091934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002111A MX2013002111A (es) 2012-02-23 2013-02-22 Metodos y composiciones para el tratamiento de metastasis del cancer.

Country Status (17)

Country Link
US (1) US8648117B2 (es)
JP (1) JP2013173741A (es)
KR (1) KR20130097121A (es)
CN (1) CN103284982A (es)
AU (1) AU2013201104A1 (es)
BR (1) BR102013004422A2 (es)
CA (1) CA2807524A1 (es)
CH (1) CH706158A2 (es)
DE (1) DE102013202928A1 (es)
FR (1) FR2987264A1 (es)
GB (1) GB2501591A (es)
MA (1) MA34504B1 (es)
MX (1) MX2013002111A (es)
NO (1) NO20130284A1 (es)
SE (1) SE1350211A1 (es)
SG (1) SG193115A1 (es)
TW (1) TW201341352A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788598T3 (es) * 2012-11-21 2020-10-22 Golden Biotechnology Corp Métodos y composiciones para tratar enfermedades neurodegenerativas
CN109069448B (zh) * 2016-02-17 2021-09-21 国鼎生物科技股份有限公司 用于治疗肝癌的组合物和方法
CN111018686B (zh) * 2019-11-19 2020-09-22 南通大学 6-苄亚基-2-芳基乙炔基环己烯酮衍生物及其制备方法和医药用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US629801A (en) 1898-07-01 1899-08-01 John O Olson Sad-iron.
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4031893A (en) 1976-05-14 1977-06-28 Survival Technology, Inc. Hypodermic injection device having means for varying the medicament capacity thereof
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5358489A (en) 1993-05-27 1994-10-25 Washington Biotech Corporation Reloadable automatic or manual emergency injection system
US5540664A (en) 1993-05-27 1996-07-30 Washington Biotech Corporation Reloadable automatic or manual emergency injection system
WO1995031235A1 (en) 1994-05-16 1995-11-23 Washington Biotech Corporation Modular automatic or manual emergency medicine injection system
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6649654B1 (en) * 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US7544189B2 (en) 2000-10-10 2009-06-09 Meridian Medical Technologies, Inc. Needle and hub assembly for automatic injector
MX2007010973A (es) * 2005-03-09 2007-09-19 Schering Corp Compuestos para inhibir la actividad de cinesina de ksp.
TW200829234A (en) 2007-01-08 2008-07-16 Golden Biotechnology Corp Antrodia camphorata isophorone extract
CN101225066B (zh) 2007-01-18 2010-09-22 国鼎生物科技股份有限公司 牛樟芝的环己烯酮萃取物
TW200918498A (en) 2007-10-19 2009-05-01 Golden Biotechnology Corp Novel compound isolated from Antrodia camphorate extracts
CN101417934B (zh) 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
TW201102076A (en) * 2009-07-09 2011-01-16 Golden Biotechnology Corp Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma
CN102000047B (zh) 2009-09-02 2012-08-08 国鼎生物科技股份有限公司 用于抑制骨癌肿瘤细胞生长的牛樟芝环己烯酮化合物
ES2574606T3 (es) 2009-11-26 2016-06-21 National Taiwan University Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma
CA2795586A1 (en) * 2011-11-15 2013-05-15 Golden Biotechnology Corporation Methods and compositions for treatment, modification and management of bone cancer pain

Also Published As

Publication number Publication date
MA34504B1 (fr) 2013-09-02
FR2987264A1 (fr) 2013-08-30
US20130225691A1 (en) 2013-08-29
AU2013201104A1 (en) 2013-09-12
SE1350211A1 (sv) 2013-08-24
DE102013202928A1 (de) 2013-08-29
CH706158A2 (de) 2013-08-30
TW201341352A (zh) 2013-10-16
JP2013173741A (ja) 2013-09-05
NO20130284A1 (no) 2013-08-26
GB201303161D0 (en) 2013-04-10
CN103284982A (zh) 2013-09-11
BR102013004422A2 (pt) 2017-09-26
CA2807524A1 (en) 2013-08-23
KR20130097121A (ko) 2013-09-02
SG193115A1 (en) 2013-09-30
GB2501591A (en) 2013-10-30
US8648117B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
MY157341A (en) Methods and compositions for treating lung cancer
IN2015DN00127A (es)
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
EP3085380A4 (en) Composition for treating prostate cancer
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
JO3755B1 (ar) تركيبات تستوستيرون
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2015007518A (es) Metodos para tratar el prurito.
PH12017501864A1 (en) Compositions and methods for treating autism
IN2013MU00848A (es)
IN2014DN09450A (es)
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
EP2994542A4 (en) Compositions for ovarian cancer assessment having improved specificity
IN2014CN00312A (es)
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
IN2014DN07103A (es)
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.
IN2014DN10209A (es)
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.